Seres Therapeutics Inc (MCRB)

Nov 27, 2024

Seres Therapeutics (NASDAQ:MCRB) Downgraded to "Sell" Rating by StockNews.com - MarketBeat

Nov 27, 2024

Nov 22, 2024

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference - The Manila Times

Nov 22, 2024

Nov 20, 2024

Seres Therapeutics CEO Eric Shaff sells shares worth $1,354 By Investing.com - Investing.com South Africa

Nov 20, 2024

Nov 20, 2024

Seres Therapeutics Q3 2024 Earnings Preview - MSN

Nov 20, 2024

Nov 20, 2024

Seres Therapeutics CEO Eric Shaff sells shares worth $1,354 - Investing.com India

Nov 20, 2024

Nov 19, 2024

Microbiomes Market to Grow by USD 1.13 Billion (2024-2028), Rising Disease Prevalence Driving Revenue, with AI Powering Market EvolutionTechnavio - The Malaysian Reserve

Nov 19, 2024

Nov 19, 2024

Seres Therapeutics chief legal officer sells shares worth $474 - Investing.com

Nov 19, 2024

Nov 19, 2024

Seres Therapeutics chief legal officer sells shares worth $474 By Investing.com - Investing.com Australia

Nov 19, 2024

Nov 19, 2024

Seres Therapeutics executive sells shares worth $397 - Investing.com

Nov 19, 2024

Nov 19, 2024

Seres Therapeutics executive sells shares worth $397 By Investing.com - Investing.com Canada

Nov 19, 2024

Nov 18, 2024

Seres Therapeutics Receives Notification from Nasdaq Regarding Bid Price Requirement - Defense World

Nov 18, 2024

Nov 15, 2024

Seres Therapeutics Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.37 loss in 3Q 2023) - Yahoo Finance

Nov 15, 2024

Nov 14, 2024

Canaccord Genuity Group Reiterates "Buy" Rating for Seres Therapeutics (NASDAQ:MCRB) - MarketBeat

Nov 14, 2024

Nov 14, 2024

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 14, 2024

Nov 14, 2024

Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ... By GuruFocus - Investing.com Canada

Nov 14, 2024

Nov 14, 2024

Earnings call: Seres Therapeutics reports key Q3 2024 milestones - Investing.com

Nov 14, 2024

Nov 14, 2024

Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ... - Yahoo Finance

Nov 14, 2024

Nov 13, 2024

Seres Therapeutics Reports Q3 2024 Results and Strategic Progress - TipRanks

Nov 13, 2024

Nov 13, 2024

Seres reports Q3 EPS from continuing operations (33c), consensus (24c) - TipRanks

Nov 13, 2024

Nov 13, 2024

Seres Therapeutics expects cash to fund operations into Q4 of 2025 - TipRanks

Nov 13, 2024

Nov 13, 2024

Seres Therapeutics Faces Nasdaq Challenge Amid Trial Success - TipRanks

Nov 13, 2024

Nov 13, 2024

Seres Therapeutics: Q3 Earnings Snapshot - New Haven Register

Nov 13, 2024

Nov 13, 2024

Seres Therapeutics reports Q3 EPS 58c, consensus (24c) - TipRanks

Nov 13, 2024

Nov 13, 2024

Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates - The Manila Times

Nov 13, 2024

Nov 13, 2024

Seres Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024

Nov 07, 2024

Seres Therapeutics (MCRB) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat

Nov 07, 2024

Nov 06, 2024

Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024 - The Manila Times

Nov 06, 2024

Nov 06, 2024

Seres Therapeutics Q3 2024 Earnings Call: MCRB Sets Key November Date | MCRB Stock News - StockTitan

Nov 06, 2024

Oct 30, 2024

Seres Therapeutics chief legal officer sells $2,939 in stock By Investing.com - Investing.com Australia

Oct 30, 2024

Oct 30, 2024

Seres Therapeutics exec von Moltke sells $2,991 in stock By Investing.com - Investing.com Canada

Oct 30, 2024

Oct 29, 2024

Seres Therapeutics executive sells shares worth $2,058 By Investing.com - Investing.com Canada

Oct 29, 2024

Oct 29, 2024

Seres Therapeutics executive sells shares worth $2,058 - Investing.com India

Oct 29, 2024

Oct 29, 2024

Seres Therapeutics executive sells stock for $2,749 By Investing.com - Investing.com Australia

Oct 29, 2024

Oct 29, 2024

Seres Therapeutics CEO Eric D. Shaff sells $6,036 in stock By Investing.com - Investing.com South Africa

Oct 29, 2024

Oct 29, 2024

Seres Therapeutics CEO Eric D. Shaff sells $6,036 in stock - Investing.com India

Oct 29, 2024

Oct 29, 2024

Seres Therapeutics chief legal officer sells $2,939 in stock - Investing.com India

Oct 29, 2024

Oct 29, 2024

Seres Therapeutics exec von Moltke sells $2,991 in stock - Investing.com

Oct 29, 2024

Oct 26, 2024

Institutions along with retail investors who hold considerable shares inSeres Therapeutics, Inc. (NASDAQ:MCRB) come under pressure; lose 17% of holdings value - Simply Wall St

Oct 26, 2024

Oct 24, 2024

This Verizon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - MSN

Oct 24, 2024

Oct 24, 2024

Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives $5.08 Consensus Price Target from Analysts - MarketBeat

Oct 24, 2024

Oct 24, 2024

Seres Therapeutics (NASDAQ:MCRB) Stock Rating Lowered by JPMorgan Chase & Co. - MarketBeat

Oct 24, 2024

Oct 23, 2024

Seres cut to underweight by JP Morgan on Vowst sale - MSN

Oct 23, 2024

Oct 23, 2024

Seres cut to underweight by JP Morgan on Vowst sale (NASDAQ:MCRB) - Seeking Alpha

Oct 23, 2024

Oct 21, 2024

Allogeneic Hematopoietic Stem Cell Transplant Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.

Oct 21, 2024